VAXX — Vaxxinity Cashflow Statement
0.000.00%
- $0.03m
- -$15.20m
Annual cashflow statement for Vaxxinity, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.2 | -40 | -137 | -75.2 | -56.9 |
Depreciation | |||||
Non-Cash Items | 1.69 | 8.12 | 42.2 | 7.79 | 6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.157 | -2.79 | 12.9 | 9.82 | -8.54 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -12.3 | -33.9 | -81 | -55.9 | -57.2 |
Capital Expenditures | 0 | -1.48 | -1.32 | -1.87 | -0.803 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -52.5 | 29.6 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 0 | -1.48 | -1.32 | -54.4 | 28.8 |
Financing Cash Flow Items | 0 | 39.3 | 2.64 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 11.1 | 66.1 | 196 | -0.167 | -1.14 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.13 | 30.7 | 114 | -110 | -29.5 |